Endomyocardial fibrosis (EMF) was first described in 1948. It is an idiopathic disorder, characterized by the formation of fibrous tissue on the endocardial aspect of one or both ventricles, resulting in a restrictive cardiomyopathy with atrial enlargement. Originally described in Uganda, numerous cases have also been described in the Middle East.
Get full access to this article
View all access options for this article.
References
1.
HassanWM, FawzyME, HelalySA, HegazyH, MalikS. Pitfalls in diagnosis and clinical, echocardiographic and hemodynamic findings in endomyocardial fibrosis. Chest2005;128:3985–92
2.
DaviesJNP. Endomyocardial fibrosis. A heart disease of obscure aetiology in Africans. East Afr Med J1948;25:10–4
3.
FawzyME, ZiadyG, HalimNM. Endomyocardial fibrosis: report of eight cases. J Am Coll Cardiol1985;5:983–8
4.
ConnorDH, SomersK, HuftMSR. Endomyocardial fibrosis in Uganda (Davies̀ disease): Part I. Epidemiologic, clinical and pathologic study. Am Heart J1967;74:687–709
5.
ConnorDH, SomersK, HuftMSR. Endomyocardial fibrosis in Uganda (Davies̀ disease): Part II. Epidemiologic, clinical and pathologic study. Am Heart J1968;75:107–24
6.
MarijonE, OuP. What do we know about endomyocardial fibrosis in children of Africa ?Pediatr Cardiol2006;27:523–4
7.
SethS, ThataD, SharmaS. Clinico-pathological evaluation of restrictive cardiomyopathy in India. Euro J Heart Fail2004;6:723–9
8.
El RamahiKM, FawzyME, SieckJO. Cardiac and pulmonary involvement in Behcet disease. Scand J Rheumatol1991;20:373–6
